134 related articles for article (PubMed ID: 12959184)
21. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
[TBL] [Abstract][Full Text] [Related]
22. Surgical Findings and Outcomes in Premenopausal Breast Cancer Patients Undergoing Oophorectomy: A Multicenter Review From the Society of Gynecologic Surgeons Fellows Pelvic Research Network.
Harvey LFB; Abramson VG; Alvarez J; DeStephano C; Hur HC; Lee K; Mattingly P; Park B; Piszczek C; Seifi F; Stuparich M; Yunker A
J Minim Invasive Gynecol; 2018 Jan; 25(1):111-115. PubMed ID: 28821472
[TBL] [Abstract][Full Text] [Related]
23. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
24. [Multicenter randomized controlled clinical study for the operative treatment of malignant ovarian germ cell tumors].
Liu Q; Ding XL; Yang JX; Cao DY; Shen K; Lang JH; Zhang GN; Xin XY; Xie X; Zhang SL; Wu YM; Zhu GH; Wang J; Chen YL; Kong BH; Zheng JH
Zhonghua Fu Chan Ke Za Zhi; 2013 Mar; 48(3):188-92. PubMed ID: 23849941
[TBL] [Abstract][Full Text] [Related]
25. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
Rutter JL; Wacholder S; Chetrit A; Lubin F; Menczer J; Ebbers S; Tucker MA; Struewing JP; Hartge P
J Natl Cancer Inst; 2003 Jul; 95(14):1072-8. PubMed ID: 12865453
[TBL] [Abstract][Full Text] [Related]
26. Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: a retrospective study and meta-analysis.
Chen J; Wang R; Zhang B; Lin X; Wei J; Jia Y; Yin Y; Ye S; Zhu T; Chen G; Yuan Y; Lu W; Li K
Am J Obstet Gynecol; 2016 Oct; 215(4):460.e1-460.e13. PubMed ID: 27133009
[TBL] [Abstract][Full Text] [Related]
27. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
[TBL] [Abstract][Full Text] [Related]
28. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?
Olivier RI; Lubsen-Brandsma LA; van Boven H; van Beurden M
Gynecol Oncol; 2005 Feb; 96(2):439-43. PubMed ID: 15661233
[TBL] [Abstract][Full Text] [Related]
29. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
30. Laparoscopic surgery of the fallopian tubes and ovaries.
Dawood MY
Semin Laparosc Surg; 1999 Jun; 6(2):58-67. PubMed ID: 10459057
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
32. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
[TBL] [Abstract][Full Text] [Related]
33. Role of minimally invasive surgery in ovarian cancer.
Nezhat FR; Pejovic T; Finger TN; Khalil SS
J Minim Invasive Gynecol; 2013; 20(6):754-65. PubMed ID: 24183269
[TBL] [Abstract][Full Text] [Related]
34. Advances in the surgical management of ovarian cancer.
Horowitz NS; Duska LR
J Reprod Med; 2005 Jun; 50(6):454-66. PubMed ID: 16050570
[TBL] [Abstract][Full Text] [Related]
35. [Wedge resection of the opposite ovary in conservative surgery of malignant ovarian tumor: is there any value?].
Kotera K; Moriyama S; Ishimaru T; Nakajima H
Nihon Rinsho; 2004 Oct; 62 Suppl 10():527-30. PubMed ID: 15535301
[No Abstract] [Full Text] [Related]
36. Current Strategy for the Treatment of Ovarian Germ Cell Tumors: Role of Extensive Surgery.
Li J; Wu X
Curr Treat Options Oncol; 2016 Aug; 17(8):44. PubMed ID: 27357180
[TBL] [Abstract][Full Text] [Related]
37. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
38. Colon resection for ovarian cancer: intraoperative decisions.
Hoffman MS; Zervose E
Gynecol Oncol; 2008 Nov; 111(2 Suppl):S56-65. PubMed ID: 18835022
[TBL] [Abstract][Full Text] [Related]
39. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
[TBL] [Abstract][Full Text] [Related]
40. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
Powell CB; Chen LM; McLennan J; Crawford B; Zaloudek C; Rabban JT; Moore DH; Ziegler J
Int J Gynecol Cancer; 2011 Jul; 21(5):846-51. PubMed ID: 21670699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
